Results 1 to 10 of about 602,989 (338)

Myofascial trigger points in migraine and tension-type headache

open access: yesThe Journal of Headache and Pain, 2018
Background A myofascial trigger point is defined as a hyperirritable spot in skeletal muscle that is associated with a hypersensitive palpable nodule in a taut band.
Thien Phu Do   +4 more
doaj   +2 more sources

Headache [PDF]

open access: yesBMJ, 2005
A 32 year old woman comes to you complaining of recurrent frontal headaches. They started about a month earlier and have been steadily increasing in frequency and intensity over the past few days. She mentions stress at work and poor sleep.
Sharon K Bal, Gary R Hollingworth
  +9 more sources

The global prevalence of headache: an update, with analysis of the influences of methodological factors on prevalence estimates

open access: yesThe Journal of Headache and Pain, 2022
According to the Global Burden of Disease (GBD) study, headache disorders are among the most prevalent and disabling conditions worldwide. GBD builds on epidemiological studies (published and unpublished) which are notable for wide variations in both ...
L. Stovner   +3 more
semanticscholar   +1 more source

Primary headache epidemiology in children and adolescents: a systematic review and meta-analysis

open access: yesThe Journal of Headache and Pain, 2023
Introduction Headache is the most prevalent neurological manifestation in adults and one of the leading causes of disability worldwide. In children and adolescents, headaches are arguably responsible for a remarkable impact on physical and psychological ...
A. Onofri   +18 more
semanticscholar   +1 more source

Early and Delayed Rebound Intracranial Hypertension following Epidural Blood Patch in a Case of Spontaneous Intracranial Hypotension

open access: yesCase Reports in Neurological Medicine, 2022
Background. Spontaneous intracranial hypotension (SIH) is a secondary headache that has been attributed to a cerebrospinal fluid (CSF) leak. It may resolve spontaneously or require conservative treatment.
Elham Jafari   +2 more
doaj   +1 more source

Psychological predictors of negative treatment outcome with Erenumab in chronic migraine: data from an open label long-term prospective study

open access: yesThe Journal of Headache and Pain, 2021
Background Monoclonal antibodies (mABs) targeting the calcitonin gene-related peptide (CGRP) pathway represent the first disease-specific preventive migraine therapy.
Bottiroli Sara   +9 more
doaj   +1 more source

Long COVID headache

open access: yesThe Journal of Headache and Pain, 2022
Headache is among the most frequent symptoms persisting or newly developing after coronavirus disease 2019 (COVID-19) as part of the so-called long COVID syndrome.
C. Tana   +10 more
semanticscholar   +1 more source

Plasma levels of CGRP and expression of specific microRNAs in blood cells of episodic and chronic migraine subjects: towards the identification of a panel of peripheral biomarkers of migraine?

open access: yesThe Journal of Headache and Pain, 2020
Background Migraine can manifest with an episodic or a chronic pattern in a continuum of disease severity. Multiple factors are associated with the progression of the pattern from episodic to chronic.
Rosaria Greco   +7 more
doaj   +1 more source

Results of a Web-based survey of 2105 Greek migraine patients in 2020: demographics, clinical characteristics, burden and the effects of the COVID-19 pandemic on the course of migraine

open access: yesBMC Neurology, 2022
The Greek Society of Migraine and Headache Patients (GSMHP), maintaining a strong commitment to research and information, conducted its second web-based online survey named "Migraine in Greece—2020", following its first one conducted in 2018.
Emmanouil V. Dermitzakis   +5 more
doaj   +1 more source

Six-month therapy of CGRP monoclonal antibodies in real-world clinical practice: an interim analysis of efficacy and safety data

open access: yesМедицинский совет, 2022
Introduction. Migraine is one of the most common disabling neurological disorders. Recently developed monoclonal antibodies to calcitonin gene-related peptide (CGRP) or its receptor are the first targeted medication for preventive therapy of both ...
N. V. Vashchenko   +5 more
doaj   +1 more source

Home - About - Disclaimer - Privacy